Genzyme Begins Phase 2 Pivotal Study of Clolar(R) and Caliper Collaborates with Invitrogen to Develop Fluorescence Kits for Optical Imaging.

0 Comments | M2 Presswire, November, 2006

M2 PRESSWIRE-29 November 2006-U.S. Equity News: Genzyme Begins Phase 2 Pivotal Study of Clolar(R) and Caliper Collaborates with Invitrogen to Develop Fluorescence Kits for Optical Imaging(C)1994-2006 M2 COMMUNICATIONS LTD RDATE:29112006 City of Industry, CA - Biotechnology industry alert provided by U.S.

Equity News. Genzyme Corporation (Nasdaq: GENZ) recently announced that it has begun treating patients in a phase 2 clinical trial examining the safety and effectiveness of Clolar (clofarabine) in previously untreated, older adult patients with acute myelogenous leukemia (AML) who are unlikely to benefit from standard induction therapy. This is Genzyme's second pivotal clinical study of clofarabine in adult patients with AML to commence this year. StemCells...